FIGO staging for carcinoma of the vulva: 2021 revision

Simple item page
dc.contributor.authorOlawaiye, Alexander B.
dc.contributor.authorCotler, Joseph
dc.contributor.authorCuello, Mauricio A.
dc.contributor.authorBhatla, Neerja
dc.contributor.authorOkamoto, Aikou
dc.contributor.authorWilailak, Sarikapan
dc.contributor.authorPurandare, Chittaranjan N.
dc.contributor.authorLindeque, Gerhard
dc.contributor.authorBerek, Jonathan S.
dc.contributor.authorKehoe, Sean
dc.date.accessioned2025-01-20T22:08:29Z
dc.date.available2025-01-20T22:08:29Z
dc.date.issued2021
dc.description.abstractTo revise the FIGO staging for carcinoma of the vulva using a new approach that involves analyses of prospectively collected data. The FIGO Committee for Gynecologic Oncology reviewed the recent literature to gain an insight into the impact of the 2009 vulvar cancer staging revision. The Committee resolved to revise the staging with a goal of simplification and actively collaborated with the United States National Cancer Database to analyze prospectively collected data on carcinoma of the vulva. Many tumor characteristics were collected for all stages of vulvar cancer treated between 2010 and 2017. Statistical analysis was performed with SAS software. Overall survival was estimated based on tumor characteristics. Log-rank and Wilcoxon tests were used to analyze overall survival similarities between and within groups of tumor characteristics. Characteristics with similar survivals were then grouped into the same stages and substages. Kaplan-Meier overall survival curves were generated for the resulting stages and substages. There were 12 063 cases with available data. The resulting new staging for carcinoma of the vulva has two substages in Stage I, no substage in Stage II, three substages in Stage III, and two substages in Stage IV. The Kaplan-Meier overall survival curves showed clear separation between stages and substages. The 2021 vulvar cancer staging is the first from the FIGO Committee for Gynecologic Oncology to be derived from data analyses. This revision has a new definition for depth of invasion, uses the same definition for lymph node metastases utilized in cervical cancer, and allows findings from cross-sectional imaging to be incorporated into vulvar cancer staging. The 2021 FIGO staging for carcinoma of the vulva is data-derived, validated, and much simpler than earlier revisions.
dc.fuente.origenWOS
dc.identifier.doi10.1002/ijgo.13880
dc.identifier.eissn1879-3479
dc.identifier.issn0020-7292
dc.identifier.urihttps://doi.org/10.1002/ijgo.13880
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94296
dc.identifier.wosidWOS:000695639800014
dc.issue.numero1
dc.language.isoen
dc.pagina.final47
dc.pagina.inicio43
dc.revistaInternational journal of gynecology & obstetrics
dc.rightsacceso restringido
dc.subjectcarcinoma
dc.subjectstaging
dc.subjectvulva
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleFIGO staging for carcinoma of the vulva: 2021 revision
dc.typeartículo
dc.volumen155
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas